Omega-3 fatty acids and lipoprotein associated phospholipase A 2in healthy older adult males and females

European Journal of Nutrition

Volumn 50, Issue 3, 2011, Pages 185-193

  Nelson, T L ^a   Hokanson, J E ^b   Hickey, M S ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Global Health and Health Disparities   (United States)

Author keywords

Healthy adults; Inflammation; Lipids; Lipoprotein associated phospholipase A2; Omega 3 fats

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 5,8,11,14,17 ICOSAPENTAENOIC ACID; ARACHIDONIC ACID; CERVONIC ACID; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINOLEIC ACID; LINOLENIC ACID; LINSEED OIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLEIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PALMITIC ACID; STEARIC ACID; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG CAPSULE; ENZYME ACTIVITY; ERYTHROCYTE MEMBRANE; FATTY ACID ANALYSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ALPHA-LINOLENIC ACID; DIET; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; FISH OILS; HUMANS; LINSEED OIL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLANT OILS; QUESTIONNAIRES; SINGLE-BLIND METHOD;

EID: 79959238956     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-010-0126-7     Document Type: Article

References (35)

1. Young J, Libby P, Schonbeck U (2002) Cytokines in the pathogensis of atherosclerosis. Thromb Haemost 88:554-567
2. Macphee CH, Nelson J, Zalewski A (2006) Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol 6:154-161 (Pubitemid 43362129)
3. Zalewski A, Macphee C, Nelson JJ (2005) Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 5:527-532 (Pubitemid 43008525)
4. Yang EH, McConnell JP, Lennon RJ et al (2006) Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26:106-111 (Pubitemid 43732235)
5. Oei HH, van der Meer IM, Hofman A et al (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111:570-575 (Pubitemid 40216483)
6. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C (2004) Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110:1903-1908 (Pubitemid 39331899)
7. Ballantyne CM, Hoogeveen RC, Bang H et al (2005) Lipoprotein- associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165:2479-2484 (Pubitemid 41720009)
8. Sudhir K (2005) Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 90:3100-3105
9. Winkler K, Winkelmann BR, Scharnagl H et al (2005) Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111:980-987 (Pubitemid 40354515)
10. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH (2000) Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150:413-419 (Pubitemid 30336554)
11. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM (2005) Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 25:216-221 (Pubitemid 40054279)
12. Weintraub H (2008) Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol 101:3f-10f
13. James M, Gibson RA, Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71:343S-348S
14. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ (1996) The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 63:116-122 (Pubitemid 26005735)
15. Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A (2003) Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 167:237-242 (Pubitemid 36773523)
16. Bemelmans WJ, Lefrandt JD, Feskens EJ et al (2004) Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. Eur J Clin Nutr 58:1083-1089 (Pubitemid 39077156)
17. Calder PC (2003) N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38:343-352
18. Macphee CH, Nelson JJ (2005) An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction. Eur Heart J 26:107-109 (Pubitemid 40282776)
19. Emken EA, Adlof RO, Gulley RM (1994) Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim Biophys Acta 1213:277-288 (Pubitemid 24262911)
20. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
21. Mantzioris E, James MJ, Gibson RA, Cleland LG (1994) Dietary substitution with alpha-linolenic acid-rich vegetable oil increases eicosapentoaenoic acid concentrations in tissues. Am J Clin Nutr 59:1304-1309
22. Mantzioris E, James MJ, Gibson RA, Cleland LG (1995) Differences exist in the relationships between dietary linoleic and alpha-linolenic acids and the respective long-chain metabolites. Am J Clin Nutr 61:320-324
23. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494 (Pubitemid 28481664)
24. Holvoet P, Martens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, de Werf F (2001) Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848 (Pubitemid 32448777)
25. Holvoet P, Satssen JM, Van Cleemput J, Collen D, Vanhaecke J (1998) Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 18:100-107 (Pubitemid 28047605)
26. Pedersen MW, Koenig W, Christensen JH, Schmidt EB (2009) The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 48:1-5
27. Schmidt EB, Koenig W, Khuseyinova N, Christensen JH (2008) Lipoprotein-associated phospholipase A2 concentrations in plasma are associatedwith the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis 196:420-424
28. Eslick G, Howe PRC, Smith C, Priest R, Bensoussan A (2009) Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. In J of Cardiology 136:4-16
29. Vickers K, Maguire CT, Wolfert R, Burns AR, Reardon M, Geis R, Holvoet P, Morrisett JD (2009) Relationship of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in carotid atherosclerosis. J Lipid Res 50:1735-1743
30. Oldgren J, James SK, Siegbahn A, Wallentin L (2007) Lipoprotein- associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 28:699-704 (Pubitemid 46439239)
31. Wootton PT, Stephens JW, Hurel SJ et al (2006) Lp-PLA2 activity and PLA2G7 A379 V genotype in patients with diabetes mellitus. Atherosclerosis 189:149-156 (Pubitemid 44441290)
32. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G (2006) The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 190:388-396
33. Albert MA, Glynn RJ, Wolfert RL, Ridker PM (2005) The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182:193-198 (Pubitemid 41188387)
34. Schaefer E, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ (2005) Effects of atorvastatin versus other statins on fasting and postprandial c-reactive protein and lipoprotein- associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95:1025-1032 (Pubitemid 40544302)
35. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W (2004) Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89:1153-1159 (Pubitemid 38368404)